EQL Pharma Management
Management criteria checks 1/4
EQL Pharma's CEO is Axel Schorling, appointed in Aug 2022, has a tenure of 1.92 years. directly owns 1.07% of the company’s shares, worth SEK17.67M. The average tenure of the management team and the board of directors is 1.9 years and 5.2 years respectively.
Key information
Axel Schorling
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.9yrs |
| CEO ownership | 1.1% |
| Management average tenure | 1.9yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22CEO
Axel Schorling (38 yo)
1.9yrs
Tenure
Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 18.5yrs | SEK 1.50m | no data | |
| President & CEO | 1.9yrs | no data | 1.07% SEK 17.7m | |
| Chief Financial Officer | 2.6yrs | no data | 0.047% SEK 779.8k | |
| Chief Operating Officer | 1.9yrs | no data | 0.052% SEK 863.4k | |
| Chief Commercial Officer | no data | no data | 0.88% SEK 14.6m | |
| Chief Business Development Officer | 1.3yrs | no data | no data |
1.9yrs
Average Tenure
50yo
Average Age
Experienced Management: EQL's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 18.5yrs | SEK 1.50m | no data | |
| Non Independent Director | 9.5yrs | no data | no data | |
| Independent Director | 4.5yrs | no data | 0.0086% SEK 142.0k | |
| Independent Director | 5.9yrs | no data | 0.034% SEK 568.0k | |
| Independent Director | 3.5yrs | no data | 0.034% SEK 568.0k | |
| Independent Director | 3.5yrs | no data | no data |
5.2yrs
Average Tenure
58yo
Average Age
Experienced Board: EQL's board of directors are considered experienced (5.2 years average tenure).